Scenic Biotech Joins Michael J. Fox Foundation’s LITE Program to Explore New Disease-Modifying ...
Collaboration will evaluate Scenic's first-in-class PLA2G15 inhibitor program in Parkinson's diseaseLeveraging MJFF’s LITE consortium and world-class LRRK2 biology and biomarker infrastructure to test ...
Proof-of-concept SHEPHERD study will assess SUL-238's effects on mitochondrial function in patients with Parkinson's disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results